Rafael Holdings Q4 net loss $12.1M ($0.28/shr); cash $52.8M; Cyclo Phase 3 continues

Rafael Holdings, Inc.

Net loss attributable to Rafael Holdings of $12.1M for Q4 vs $4.5M year ago; FY net loss $30.5M ($1.04/shr).
Research and development expenses rose to $7.5M in Q4 from $1.5M year ago on Cyclo Therapeutics consolidation.
Closed $25M rights offering in June 2025, including $21M backstop from the Jonas family; cash $52.8M at July 31.
Cyclo’s Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 continues after DMC review at 48 weeks.
Joshua Fine elected Chief Operating Officer effective August 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.